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Abstract
Chordoma is a rare tumor arising in the sacrum, clivus, or vertebrae. It is often not completely resectable and shows a
high incidence of recurrence and progression with shortened patient survival and impaired quality of life. Chemo-
therapeutic options are limited to investigational therapies at present. Therefore, adjuvant therapy for control of tumor
recurrence and progression is of great interest, especially in skull base lesions where complete tumor resection is often
not possible because of the proximity of cranial nerves. To understand the extent of genetic instability and associated
chromosomal and gene losses or gains in skull base chordoma, we undertook whole-genome single-nucleotide
polymorphism microarray analysis of flash frozen surgical chordoma specimens, 21 from the clivus and 1 from C1 to
C2 vertebrae. We confirm the presence of a deletion at 9p involving CDKN2A, CDKN2B, and MTAP but at a much
lower rate (22%) than previously reported for sacral chordoma. At a similar frequency (21%), we found aneuploidy of
chromosome 3. Tissue microarray immunohistochemistry demonstrated absent or reduced fragile histidine triad (FHIT)
protein expression in 98% of sacral chordomas and 67%of skull base chordomas. Our data suggest that chromosome 3
aneuploidy and epigenetic regulation of FHIT contribute to loss of the FHIT tumor suppressor in chordoma. The finding
that FHIT is lost in a majority of chordomas provides new insight into chordoma pathogenesis and points to a potential
new therapeutic target for this challenging neoplasm.
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Introduction
As a primary tumor of the notochord-derived axial skeleton,
chordoma is a rare entity with incidence ranging from 0.051 to
0.8 per 100,000 persons per year [1–3]. Because of the predilection
for sacral and skull base lesions, surgical resection is often incom-
plete. The remnant tumor cells, although slowly growing, eventually
reform the tumor bulk and can progress to a more malignant state
with metastatic deposits to bone, lung, or liver [3–7]. Chemothera-
peutic or biologic therapies for the treatment of chordoma are in pre-
clinical and early clinical trials, with no curative therapy presently
available to patients [8]. Proton beam radiation to the surgical bed
has been shown beneficial with increased progression-free survival
[9,10]; however, our understanding of the radiobiology and chemo-
therapeutic resilience of chordoma is incomplete.
Unbiased surveys of the chordoma genome can serve as a strategy
for the generation of novel hypotheses about tumor pathogenesis and
therapy as well as adding to our understanding of genetic aberrations
unique to chordoma or common to other cancers. As such, this type of
study serves to develop a basic knowledge of the fundamental alter-
ations in the DNA code, which are associated not only with chordoma
but also with neoplasia in general. In the setting of chordoma, it also
serves to interrogate the genetic landscape in cells that are believed to
originate from primitive notochord remnants. Multiple techniques for
genetic analysis have been applied to chordoma previously including
G banding, comparative genomic hybridization (CGH), fluorescence
in situ hybridization (FISH), and spectral karyotype analysis. These
studies have identified normal karyotypes in a majority of chordomas
[11], a greater propensity for chromosomal losses [12], and documented
the absence of consistent structural chromosomal aberrations in all
chordomas. Aberrations in chromosomes 1, 3, 4, 12, 13, and 14 have
been associated with chordoma recurrence [11,13,14]. Chromosomal
changes have also been documented in chromosomes 2, 5, 6, 7, 9,
10, 17, and 20 [15–18]. The biologic significance of 1q and 9p loss
and 7q gain and implications for therapeutic intervention have been
recently reviewed [8]. Aberration of chromosome 3 by G banding anal-
ysis has been observed in 62% of skull base chordomas and complete
loss of chromosome 3 or the 3p arm has been reported in chordoma
with a frequency of 50% to 75% by CGH [12,19,20]. However, no
specific tumor suppressor gene on chromosome 3 has yet been associated
with chordoma.
In this study, whole-genome single-nucleotide polymorphism (SNP)
microarray analysis was used to survey the genomic landscape of
skull base chordomas. We document aneuploidy of chromosome 3
in tumors from 3 of 18 patients with a diagnosis of primary classic clival
chordoma and in one recurrent tumor. The tumor suppressor fragile
histidine triad (FHIT ) resides on chromosome 3p14.2 and has been
implicated in cancers in tissues arising from all three germ cell layers.
Screening for changes in FHIT protein expression in skull base and
sacral chordomas on tissue microarrays showed a significant level
of reduced FHIT expression that may have important implications
for chordoma pathogenesis and therapy.
Materials and Methods
Patients and Tumor Tissues
Patients diagnosed with skull base lesions with imaging features
suggestive of chordoma or their surrogate decision maker in the case
of pediatric patients gave informed consent for investigational use of
tumor tissue. Patient samples were derived from the neurosurgical
service in the Institute of Neurologic Sciences, University of Marmara
(Istanbul, Turkey; n = 22) and at St. Michael’s Hospital (Toronto,
Ontario, Canada; n = 4). Ethical approval for investigational use of
tumor tissue was obtained from the Committee for Ethical Medical
Research of the University of Marmara and the St. Michael’s Hospital
Research Ethics Board. Tumor specimens obtained at the time of sur-
gical resection were frozen in liquid nitrogen or fixed in formalde-
hyde. A pathological diagnosis was made by immunohistology and
hematoxylin and eosin (H&E) histology by the neuropathologist.
Chondroid chordomas were differentiated from classic chordomas
by the presence of a hyaline cartilaginous matrix [21,22].
DNA Extraction and Quality Control
Genomic DNA from 22 fresh frozen tumors was isolated by sodium
dodecyl sulfate/Proteinase K tissue digestion followed by phenol extrac-
tion and stored in tris-ethylenediaminetetraacetic acid (TE) buffer as
described previously [23]. The quality of the DNA samples was evaluated
by agarose gel electrophoresis before submission to The Centre for Applied
Genomics, The Hospital for Sick Children (Toronto, Ontario, Canada)
for hybridization to the Affymetrix Human Mapping 500K platform.
SNP Array and Data Analysis
DNA from 22 samples was prepared as previously described [23] and
hybridized to Affymetrix Human Mapping 500K Arrays (Affymetrix,
Santa Clara, CA), which are comprised of an Sty array and an Nsp array.
The Sty array is capable of genotyping approximately 238,000 SNPs,
whereas the Nsp array can genotype approximately 262,000 SNPs. Data
analysis was performed using dChip 2006 [24,25] and CNAG 2.0 [26]
software applications. CEL files were imported into dChip, and the probe
signals were quantile normalized and modeled. Raw copy number esti-
mates were generated using normal diploid samples from Marshall et al.
[27] and subsequently segmented using the circular binary segmentation
(CBS) algorithm [28]. The segmented copy number profiles were visual-
ized in IGV [29]. Focal deletions and amplifications were defined as gain
or loss of >10 SNPs and <12 Mb in size. The list of gene loci showing
focal deletion or amplification was then analyzed using Ingenuity Path-
ways Analysis (Ingenuity Systems, www.ingenuity.com) for gene function,
identification of canonical pathways, and gene network determination.
Tissue Microarray and Tissue Section Immunohistochemistry
A skull base chordoma and a sacral chordoma tissue microarray was
immunostained for FHIT protein using rabbit anti-FHIT (HPA018840;
Sigma, St Louis, MO) antibody at 1:30 dilution on a Leica BOND-
MAX machine using the Leica Polymer Refine Kit (Leica Microsystems,
Wetzlar, Germany). Pretreatment was done for 20 minutes using Leica
ER2 solution. The positive control was normal kidney tissue. Immuno-
staining for the FHIT protein on the tissue microarray was scored by
Dr Flanagan. A second pathologist (Dr Roberto Tirabosco) scored the
samples blinded to the results of the first scoring. Staining data were
available on 85 sacral and 49 skull base tumors. The staining intensity
recorded was converted into a graded scale with the following values (0—
none, 0.5—equivocal, 1—minimal, 2—moderate, 3—intense). The
average score from two core samples if available was determined. The
frequency of samples falling into each category of staining was deter-
mined, and Chi-square analysis was performed to determine statistical
significance at a P value of .05 in frequency within each category between
sacral and skull base chordomas. To assess for tissue heterogeneity in
FHIT expression, we performed immunohistochemistry on sections
from a set of four chordomas for which tumor-positive blocks were
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available. Formalin-fixed paraffin-embedded sections were obtained at a
thickness of 4 μm. Sections were dewaxed in paraffin and rehydrated
through decreasing concentration of ethanol. Antigen retrieval was per-
formed by heating in citrate buffer (pH 6.0). Endogenous peroxidase
activity was blocked with hydrogen peroxide. Rabbit anti-FHIT
(HPA018840; Sigma) was used at a dilution of 1:30. Vector Elite
avidin-biotin complex method detection system (Vector Laboratories,
Burlington, Canada) was used with 3,3′-diaminobenzidine as the
chromogenic substrate and hematoxylin as counterstain. Slides were
visualized and photographed using a Leica DM4500B microscope
and reviewed by a neuropathologist (Dr Munoz).
Results
The present study includes genomic analysis of 22 tumor samples
including one recurrent tumor (12 females and 9 males; median,
38 years; range, 12 to 83 years; Table 1). Nineteen of the tumors were
diagnosed as classic chordoma, whereas three were chondroid chor-
doma. Twenty-two tumors were located in clivus and one was located
at the C1 to C2 vertebral level. Twenty-one tumors were primary le-
sions, whereas one was a local recurrence of tumor 6 years after initial
resection (CHD20, primary is CHD19). Additionally, three primary
chordomas and one recurrent clival chordoma (two males and two
females; range, 22–78 years) were assessed for FHIT expression by
immunohistochemistry of whole tissue sections. Core samples from
sacral and skull base chordomas were assessed for FHIT protein ex-
pression by immunohistochemistry on tissue microarrays as described
in Materials and Methods. These samples originated from patients in
the United Kingdom over long time periods and no clinical data were
available for analysis.
Table 1. Patient Demographics and Tumor Features.
ID Age Sex Location Pathology
CHD1 32 M Clivus Classic
CHD2 42 F Clivus Classic
CHD3 65 M Clivus Classic
CHD6 12 F Clivus Classic
CHD7 13 F Clivus Classic
CHD8 22 F Clivus Classic
CHD9 36 M C1–C2 Chondroid
CHD10 26 F Clivus Classic
CHD11 83 F Clivus Classic
CHD12 63 F Clivus Classic
CHD13 55 F Clivus Chondroid
CHD14 22 F Clivus Chondroid
CHD15 51 M Clivus Classic
CHD16 42 F Clivus Classic
CHD17 35 M Clivus Classic
CHD18 38 M Clivus Classic
CHD19 31 F Clivus Classic
CHD20 37 F Clivus Classic, Recurrence of CHD19
CHD21 43 M Clivus Classic
CHD22 35 F Clivus Classic
CHD23 65 M Clivus Classic
CHD26 50 M Clivus Classic
Figure 1. Frequency of DNA copy number changes detected by SNP array analysis in 22 skull base chordomas. Losses weremore frequent
than gains.
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Whole-genome SNP analysis shows that losses are more frequent
than gains in skull base chordomas. At a deletion z-score > 2 or <0.5
and q-value < 0.05, the following deletions were identified as having
broad significance: 3p (661 genes), 3q (732 genes), 9p (275 genes), 9q
(731 genes), 10p (248 genes), 10q (817 genes), 13q (400 genes), 14q
(874 genes), and 22q (598 genes). The significant chromosomal gains
identified were 7p (390 genes), 7q (815 genes), 19p (721 genes), and
19q (1055 genes). Amplification and deletion frequencies, z-scores,
and q-scores are provided in Table W1. The frequency of DNA copy
number changes detected by SNP analysis with their genomic posi-
tions is shown in Figure 1, and genomic imbalances detected for indi-
vidual tumor samples are shown in Figure 2. Focal amplifications (n =
43) were more commonly observed than focal deletions (n = 25) as
listed in Table W2. Only three focal deletions (9p: 21.800–22.032 Mb,
3 genes; 15q: 18.427–20.060 Mb, 15 genes; 23: 0.019–2.700 Mb,
0 gene) and one focal amplification (14: 19.273–19.490 Mb, 6 genes)
were observed in 2 or more of the 22 chordomas analyzed. Chromo-
thripsis was observed in 2 of 18 primary clival chordomas (CHD8 and
CHD1) on chromosomes 7 and 22, respectively (Figure 3). A total of
370 genes were found in focal amplifications and 98 genes in focal
deletions. Ingenuity pathway analysis could be performed on 305 of
370 (82%) focally amplified genes and 96 of 98 (98%) of the focally
deleted genes.
The three most common functions for genes found within focally
amplified regions were cell morphology, apoptosis, and cell-cell signal-
ing and interaction. A total of 14 amplified gene networks (>10 genes)
were identified with five overlapping networks having major nodes of
interaction with TGFB1, NFKBIA, STAT1, SMAD 3, and CTNNB1.
Analysis of canonical pathways affected by gene amplification revealed
alterations in embryonic stem cell developmental signaling and DNA
methylation pathways (Figure 4, A and B). Importantly, we observed a
focal amplification (6q: 164.424–170.748 Mb) involving the T-gene
locus in 1 of 18 (CHD17) primary classic clival chordomas and ampli-
fication of a large segment of chromosome 6 containing the T-gene
(6: 0.110391–170.748 Mb) in 4 of 18 primary classic clival chordomas
and 1 of 3 primary chondroid skull base chordomas. Focally deleted
genes mapped onto four gene networks (>10 genes) with the most
frequent function within these networks being cell cycle regulation.
Furthermore, the canonical pathways most frequently affected by focal
gene deletion were those involved in cell cycle checkpoint control
(Figure 4C ). Importantly, we observed focal deletion of CDKN2A,
CDKN2B, and CHEK2 genes.
A 199,276,135-bp loss of chromosome 3 that includes the FHIT
gene (chr3: 59,735,035–61,237,132) was observed in 3 of 19 classic
chordoma (CHD17, 20, 26) specimens. This same region was
amplified in 1 of 19 classic chordomas (CHD3). Acquired loss of
Figure 2. Genomic imbalances detected in individual tumor samples. Gains (red) and losses (blue) of genomic material were detected in
all tumor samples by SNP array analysis. Each row corresponds to a unique sample and each column represents a specific chromosome.
Chondroid and classic chordoma samples have been grouped to facilitate comparison. Note the acquisition of chromosome 3 loss and
the similarity of gains and losses in the recurrent tumor sample (CHD20) to the primary tumor sample (CHD19).
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chromosome 3 is observed in a classic chordoma at recurrence
(CHD20) 76 months after first resection but was not observed at
the time of initial surgery (CHD19). Minimal, equivocal, or no
FHIT immunostaining was observed in 83 of 85 (98%) sacral chor-
domas and 33 of 49 (67%) skull base chordomas. In addition, the
FHIT expression profile is significantly different in sacral chordomas
compared to skull base chordomas (P < .001), demonstrating a broad
range of FHIT protein expression in skull base chordomas (Figure 5).
The staining pattern of FHIT in clival chordoma is cytoplasmic and
nuclear with prominence of nucleolar staining. Variation in staining
intensity was observed between tumors (Figure 6, B–E ) and within
tumors (Figure 6, E and F ). In regions of inflammation within the
tumors, macrophages that had very intense nuclear and cytoplasmic
staining that was much more prominent than staining in adjacent
physaliferous chordoma cells were observed (Figure 6F ).
Discussion
There are few genome-wide studies of chordomas. In a recent review
of the literature, only 82 chordomas are reported with karyotype
analysis [30]. Most chordomas have been reported to have near-
diploid or moderately hypodiploid karyotypes [12]. Aneuploidy in
chordoma has been a feature associated with poor clinical outcome
for many years [31,32]. Recently, skull base chordomas with abnor-
mal karyotypes were demonstrated to have higher recurrence rates
(45% vs 3%) at an average of 48 months follow-up and were asso-
ciated with shorter patient survival [11]. The largest series of whole-
genome analysis has 30 classic chordoma tumor samples obtained
from the sacrum, coccyx, or thoracic vertebra of 26 patients [12]. In
that study, 15 of the cases had deletions affecting chromosome 9p21.3
covering the CDKN2A locus, which were identified by array CGH,
FISH, or G banding. In our study, we also found 9p deletions involv-
ing regions that included the CDKN2A locus in 4 of 18 (22%) primary
classic clival chordomas (FigureW1). More specifically, CHD3 showed
a homozygous (235,401 bp) focal deletion and CHD8 a heterozygous
focal deletion (426,901 bp), encompassing C9orf53, CDKN2A, and
CDKN2B genes completely and the MTAP gene incompletely. Thus,
whereas CDKN2A loss is observed in a small proportion of clival chor-
domas, it is much less frequent than that reported for sacral chordomas
(70%) [12]. Scheil et al. have studied 16 chordomas (10 sacrococcygeal,
5 sphenooccipital, 1 spinal) by CGH and verified DNA sequence losses
most prevalently at 3p (five of seven primary tumors) and 1p, whereas
gains were observed on chromosomes 20, 7q, 5q, and 12q [19]. Sawyer
et al. found cytogenetic abnormalities in 11 of 22 skull base and cervical
chordoma samples by using G banding and spectral karyotyping meth-
ods. Karyotype abnormalities occurred exclusively in recurrent tumors
and the recurrent alterations involved isochromosome 1q and mono-
somy of chromosomes 3, 4, 10, 13, and 18 [14]. In our study, we
found isochromosome 1q (4 of 18), chromosome 3 loss (3 of 18),
and 7q gain (11 of 18) in primary skull base chordoma samples that
support the validity of the data set. Comparison of broad significance
copy number changes observed in this study with those previously re-
ported shows that chromosome 7 gains and chromosome 3 losses are
observed in both sacral and clival chordomas, whereas sacral chordomas
have several unique chromosomal losses and gains, which are not ob-
served in our series of clival chordomas (Table 2) [12,19,33]. Another
important observation is that there appears to be greater genomic copy
Figure 3. Map of chromothripsis found in chromosome 22 in CHD1 and chromosome 7 in CHD8. There are 43 genes affected on
chromosome 22 and 32 genes affected on chromosome 7.
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Figure 4. Gene network maps for the top networks formed by genes found (A, B) within focal amplifications and (C) within focal deletions.
Gray nodes indicate deleted or amplified genes, whereas white nodes are interacting genes not part of focal amplifications or deletions.
Solid lines indicate direct protein interaction. Solid arrows indicate direct action on and dashed arrows indicate indirect action on.
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number alterations in sacral chordomas, which are seen in an older
patient population, compared to the clival chordomas that are found
in a younger patient population (Table 2). Although there were
no frequent recurrent copy number alterations in the clival chor-
domas analyzed, we identified focal amplifications and deletions
encompassing gene networks that mapped to specific functional
domains. Ingenuity pathway analysis demonstrated that gene loci
located within amplifications were associated with embryonic stem
cell signaling and DNA methylation, whereas genes located within
focal deletions were primarily involved in cell cycle regulation. The
importance of embryonic stem cell signaling in chordoma has been
highlighted recently by the finding that gain of the T-gene locus
is not only present in familial but also sporadic chordoma and that
T-gene expression is required for chordoma cell proliferation in vitro
and in vivo [34–36]. Furthermore, the observation of stem cell be-
havior in chordoma cells expressing the CD133 stem cell marker
further supports the importance of stem cell signaling in chordoma
[37]. The T-gene amplification frequency ranges from 0% to 54%
in studies with mixed populations of sacral, spinal, and clival spo-
radic chordomas. In this study, 5 of 18 (28%) primary clival chor-
domas showed copy number gain of the T-gene. This suggests that
while clival chordomas share pathogenetic mechanisms similar to
those previously reported in genomic studies biased toward sacral
chordomas, Brachyury expression in some of these tumors may be a
result of epigenetic changes triggered by initiating genomic events other
than T-gene amplification.
Deletion, rearrangement, or loss of heterozygosity in 3p is frequently
reported in lung [38–41], renal [42], nasopharyngeal [43], cervical
[44], and breast cancers [45]. We have observed a chromosome 3 gain
or loss encompassing an ∼200-Mb region mapping to 3p26.3-3q26.1
in 4 of 19 (21%) classic skull base chordomas. This observation is in
keeping with a previous study by Bayrakli et al., in which FISH anal-
ysis of clival chordomas showed deletion or amplification of 3p12-p14
in 2 of 6 primary and 2 of 10 recurrent tumors [15]. Furthermore, it is
interesting to note that the chromosome 3 loss is observed in a recurrent
clival chordoma (CHD20) but not in the primary tumor sample
(CHD19). An association between chromosome 3 aberration on cyto-
genetic analysis of skull base chordomas and both high tumor recur-
rence rate and decreased survival time has been reported [11].
The ∼1.5-Mb FHIT gene is found at 3p14.2 and is contained within
a common fragile site (FRA3B), rendering it susceptible to deletion
breakpoints and rearrangements induced by environmental carcinogens
or replicative stress [46–49]. The FRA3B fragile site is not associated
with triplet nucleotide repeats but contains adenine-thymine (AT)-
dinucleotide-rich sequences that produce high DNA helix f lexibility
and generate secondary structures that can impede DNA replication
[49]. Other mechanisms for instability at the FRA3B site include pau-
city of replication initiation events [50], late replication [51], ineffi-
cient activation of origins of replication [52], and formation of RNA
transcript/DNA hybrid complexes [53]. Deletions involving FHIT
have been reported in small cell and non–small cell lung cancer [39], pan-
creatic adenocarcinoma [54], head and neck squamous cell carcinoma
Figure 5. Histogram showing tissue microarray scoring for FHIT protein immunostaining in skull base and sacral chordomas. A score of 0
represents no staining, 0.5 equivocal staining, 1 minimal staining, 2 moderate staining, and 3 intense staining.
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[55], esophageal adenocarcinoma [56], and renal cell carcinoma [57].
Furthermore, loss of FHIT expression and aberrant transcripts are
found in glioblastoma multiforme and breast cancer [58–60]. Spon-
taneous tumors arise in both homozygous and heterozygous FHIT
knockout mice [61]. FHIT encodes a 147 amino acid cytoplasmic
protein that functions enzymatically as a diadenosine 5′,5′″-P1,P3-
triphosphate hydrolase, catalyzing the cleavage of P(1)-P(3)-bis(5′-
adenosyl) triphosphate to yield AMP and ADP [62]. However, the
tumor suppressor function of FHIT does not appear to require hydro-
lase activity because mutant FHIT with amino acid substitution at
the catalytic active site inhibits gastric and lung cancer cell line–derived
tumor growth in vivo [63].
Multiple antitumor functions for FHIT have been described includ-
ing transcriptional regulation of the cell cycle [64,65], modulation of
DNA damage checkpoint response [66,67], and enhancement of mito-
chondrial calcium uptake triggered by apoptosis-inducing factors [68].
We observed a high rate of reduced or absent FHIT protein expression
in sacral (98%) and skull base chordomas (67%), but only 21% of
classic clival chordomas demonstrated a chromosomal loss or gain en-
compassing the FHIT locus. This suggests that epigenetic mechanisms
in addition to genomic instability are involved in the determination of
FHIT expression in chordoma. Both of these mechanisms may also be
important in chordoma pathogenesis. Support for epigenetic regulation
of the FHIT locus in cancer cells is the observation that even in the ab-
sence of DNA or RNA alterations, FHIT protein expression was found
to be absent or reduced in some cancer cell lines [69]. In lung cancer,
breast cancer, and clear cell renal carcinoma, loss of FHIT gene expres-
sion correlates with DNA methylation within a 5′ CpG island [70,71].
Furthermore, in esophageal squamous cell carcinoma cell lines show-
ing transcriptional repression of FHIT, the 5′ CpG island of FHIT is
Figure 6. Immunostaining for FHIT protein in four different classic clival chordomas. (A) Secondary antibody–only control; scale bar, 50 μm.
(B) Moderate staining in a region of physaliferous cells, 22-year-old female; scale bar, 50 μm. (C) Minimal cytoplasmic staining andmoderate
nucleolar staining in a tumor from a 39-year-old female; scale bar, 50 μm. (D) Intense staining of nucleoli and variable cytoplasmic staining in
a tumor from a 78-year-old male; scale bar, 50 μm. (E) Regions of moderate cytoplasmic staining juxtaposed with regions of no cytoplasmic
staining in a recurrent tumor from a 44-year-old male; scale bar, 0.5 mm. (F) Intense cytoplasmic and nuclear staining in tumor-associated
macrophages; scale bar, 50 μm.
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methylated [72]. Treatment of these cells with 5-aza-2′-deoxycytidine
resulted in demethylation and FHIT mRNA transcription [72]. Bisul-
fite sequencing of the 5′CpG island at the FHIT locus in skull base and
sacral chordoma surgical specimens and concurrent evaluation of FHIT
mRNA and protein expression will further define the extent to which
epigenetic changes contribute to chordoma pathogenesis. Because aber-
rant FHIT transcripts have been previously reported in other tumor
types and we observe protein mislocalization to nucleoli rather than
cytoplasm in clival chordomas, analysis of FHIT mRNA transcripts
may provide further details as to FHIT protein dysfunction in chordoma.
It has not escaped our notice that reactivation of FHIT gene transcrip-
tion by the use of DNA methyltransferase and/or histone deacetylase in-
hibitors could open new therapeutic options for patients with chordomas
showing loss of FHIT expression without chromosomal deletion. Fur-
thermore, the FHIT deficiency in chordomas may explain the biologic
resistance of chordomas to ionizing radiation as it has been shown that
FHIT gene inactivation increases cell survival after DNA damage by
activation of DNA checkpoints regulated by the ataxia telangiectasia-
related protein kinase (ATR)/checkpoint kinase 1 (CHK1) pathway
[73]. In chordomas with deletion of the FHIT gene, reintroduction of
FHIT gene expression by viral or nonviral methods could potentially
render the tumor radiosensitive. Interestingly, adenoviral vector expression
of FHIT in tumor cells has been shown to induce apoptosis and im-
pair the growth of non–small cell lung cancer [74], breast cancer [75],
esophageal cancer [76], and pancreatic cancer [77] in animal models.
Whole-genome SNP analysis of skull base chordomas demonstrates
that these tumors share similar pathogenetic mechanisms that involve
loss of cell cycle checkpoint regulation and activation of signaling path-
ways involved in embryonic stem cell signaling. Despite these similar-
ities, it appears that skull base chordomas have less frequent recurrent
focal deletions and amplifications than sacral chordomas. Furthermore,
loss of FHIT expression is more common in sacral than skull base chor-
domas and appears to be a feature of recurrent skull base chordomas. As
such, loss of the tumor suppressor effects of FHIT could be an early or
Table 2. Comparison of Tumor Location, Patient Age, and Recurrent Copy Number Alterations in Copy Number Studies of Chordomas.
Study Diaz et al. (this study) Le et al. [33] Hallor et al. [12] Scheil et al. [19]
Total number of tumors 22 20 26 16
Location
Clivus 21 2 0 5
Mobile spine 1 7 2 1
Sacrum 0 11 24* 10
Primary samples 19 17 18 7
Median age (years) 38 61.5 60 61
Platform Affymetrix 500K Agilent 250K BAC array CGH CGH
Broad significance copy number
changes† (frequency)
Gains 1q21.1-q25.2; 1q31.3-q43
5p15.33; 5q31.1-q31.2; 5q35.1-q35.3 5q (0.38)
6q25.3-q27
7 (0.68) 7p36.3-p22.3 (0.25) 7 7q (0.69)
8q24.3 (0.35) 8q24.21-q24.22
11q12.2-q13.4 (0.30)
12p13.33-p12.1; 12q13.11-q13.13 12q (0.38)
15q11.2
16q21-q22.2
17q11.1-q25.3 (0.25)
19p (0.55); 19q (0.55) 19p13.3-q13.43 (0.30) 19p13.3-p13.2; 19q12-q13.43
20q11.21-q13.12; 20q13.33 20 (0.50)
Losses 1p36.33-p11.1 1p (0.44)
2q34-q37.3
3 (0.45) 3p29-p26.3 (0.75) 3 3p (0.5)
4p16.3-q35.2 (0.40) 4
6q21-q22.33 (0.25) 6p21.1
7q11.22-q11.23
8p12-p11.1
9p24.3-q34.3 (0.25) 9p24.3-q31.3; 9q33.3-q34.3
10p (0.61); 10q (0.57) 10p15.3-q26.3 (0.65) 10
11p15.5-p11.12 (0.30) 11p15.5-p15.3; 11p14.3-p11.2; 11q12.2-q13.2; 11q14.3-q25
12p11.21-p11.1; 12q24.31
13q (0.61) 13q11-q34 (0.60) 13
14q (0.65) 14q11.1-q32.33 (0.65) 14
15q11.2; 15q15.1-q21.1
16p13.3; 16p12.3-q24.3
17p13.3-p11.1 (0.35) 17p13.3-p11.1; 17q25.1-q21.3
18p11.32-q23 (0.40) 18
19p13.3-p11
19q13.11-q13.43
20p11.21-q11.21
22q (0.71) 22q11.1-q13.33 (0.45)
21q22.2-q22.3
Xp22.33
Yp11.2; Yq11.22-q11.23
*Includes 4 coccyx chordomas and 20 sacral chordomas.
†All four studies differ in the reporting of significant broad copy number alterations. We use z-scores of >2 or <0.5 and q-values < 0.05 regardless of frequency. Long et al. list copy changes occurring in
>25% of cases. Hallor et al. report copy changes occurring in greater than or equal to five cases with individual frequencies not provided. Scheil et al. reports the most frequent gains and losses.
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predisposing event in sacral chordomas and a feature associated with
therapy resistance in chordomas of the skull base. We describe for
the first time a specific gene (FHIT) in the chromosome 3 short arm,
for which loss of gene expression is a frequent feature of both sacral and
skull base chordomas. The absence or reduced expression of FHIT in
sacral and skull base chordomas suggests a possible new therapeutic tar-
get for treatment of this ultimately debilitating and lethal tumor and
provides new insight into chordoma pathogenesis and radioresistance.
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Table W1. Broad Significance Copy Number Chromosomal Loss or Gain Analysis for 22 Skull Base Chordomas.
Arm No. of Genes Amplification Frequency Amplification z-Score Amplification q-Value Deletion Frequency Deletion z-Score Deletion q-Value
1p 1423 0 −1.99 0.977 0.39 1.98 0.0899
1q 1274 0.18 −0.459 0.977 0.3 0.83 0.529
2p 590 0.29 0.557 0.805 0.12 −1.14 0.994
2q 1017 0.25 0.244 0.977 0.17 −0.612 0.994
3p 661 0.08 −1.33 0.977 0.45 2.46 0.0304
3q 732 0.08 −1.32 0.977 0.45 2.47 0.0304
4p 291 0.07 −1.57 0.977 0.36 1.37 0.257
4q 667 0.07 −1.43 0.977 0.41 1.95 0.0899
5p 169 0.35 1.14 0.499 0.19 −0.503 0.994
5q 1009 0.35 1.31 0.412 0.19 −0.379 0.994
6p 768 0.3 0.831 0.648 0 −2.19 0.994
6q 550 0.3 0.785 0.648 0 −2.22 0.994
7p 390 0.68 4.9 9.57E − 06 0.12 −0.748 0.994
7q 815 0.68 5.03 9.57E − 06 0.12 −0.709 0.994
8p 370 0.13 −1.21 0.977 0 −2.5 0.994
8q 554 0.13 −1.18 0.977 0 −2.48 0.994
9p 275 0.08 −1.27 0.977 0.5 2.86 0.0137
9q 731 0 −1.9 0.977 0.48 2.8 0.0143
10p 248 0 −1.69 0.977 0.61 4.14 0.000169
10q 817 0 −1.73 0.977 0.57 3.81 0.000537
11p 578 0.2 −0.364 0.977 0.16 −0.788 0.994
11q 1048 0.14 −0.917 0.977 0.1 −1.35 0.994
12p 374 0.14 −1.02 0.977 0.1 −1.45 0.994
12q 943 0.14 −0.933 0.977 0.1 −1.37 0.994
13q 400 0 −1.67 0.977 0.61 4.18 0.000169
14q 874 0 −1.54 0.977 0.65 4.82 2.79E − 05
15q 776 0.16 −0.757 0.977 0.2 −0.33 0.994
16p 585 0.2 −0.363 0.977 0.16 −0.787 0.994
16q 456 0.2 −0.384 0.977 0.16 −0.806 0.994
17p 420 0.43 2.06 0.111 0.14 −0.829 0.994
17q 1086 0.41 2.05 0.111 0.07 −1.38 0.994
18p 93 0.13 −0.987 0.977 0.38 1.48 0.226
18q 265 0.12 −1.07 0.977 0.33 1.01 0.439
19p 721 0.55 3.48 0.00243 0.09 −1.11 0.994
19q 1055 0.55 3.57 0.00228 0.09 −1.07 0.994
20p 249 0.33 0.927 0.627 0.29 0.523 0.733
20q 528 0.37 1.37 0.412 0.25 0.139 0.994
21q 324 0.14 −1.03 0.977 0.1 −1.46 0.994
22q 598 0.55 2.44 0.0575 0.71 4.59 4.25E − 05
Table W2. Focal Deletions and Amplifications in 22 Skull Base Chordomas.
Chromosome Start End Chordoma Copy Number
1 64010000 64258800 1 2.9785
1 73415100 73597100 1 2.7531
3 1.14E + 08 1.14E + 08 13 3.1337
6 6956840 7041070 6 3.2562
6 1.64E + 08 1.71E + 08 17 2.9556
7 17740800 18224800 8 3.1441
7 21259200 22677900 8 2.848
7 23176700 25324300 8 2.8286
7 26599600 27037100 8 2.7276
7 28169700 28332900 8 2.5539
7 1.05E + 08 1.05E + 08 21 3.6597
8 180568 2290330 3 2.3167
8 2291450 2555870 3 3.0804
10 44557600 44649400 16 2.913
11 18905800 18916600 15 3.6039
11 57188600 57488200 3 3.3231
11 88751000 88984700 18 3.2482
13 64426400 64876100 26 3.018
14 19273000 19492400 2 3.2352
14 19273000 19490000 13 3.3815
14 19273000 19492400 22 3.5283
15 18427100 20329200 6 2.8686
15 19821400 20059900 10 3.1342
16 83196000 83226300 2 3.118
17 6888 595982 23 2.4384
17 31427100 31501500 6 2.9558
17 41006800 41022700 3 3.8239
17 41521600 41647900 3 3.258
18 41802200 42497500 8 2.949
18 54560000 54957300 9 2.7628
19 9911180 12049300 26 3.5655
20 704982 757930 2 3.2953
20 23030400 23093300 3 3.1663
20 29310000 34285700 3 3.2411
20 46286500 46420700 3 2.4006
22 21048600 21487500 1 2.6534
22 26496400 26571300 1 3.4285
22 27558000 27839300 1 2.6784
22 31421600 31600500 1 2.7299
22 38030700 38499900 1 2.7776
22 40758200 41196600 1 2.9287
23 6505280 6662160 6 2.8086
23 7548890 8051920 6 2.4649
1 1.93E + 08 1.96E + 08 11 1.1955
2 1.1E + 08 1.1E + 08 3 0.3366
8 4117730 4203330 13 0.9329
9 10977800 11895600 2 1.222
9 11903200 12061200 17 0.9162
9 21796600 22032000 3 0.3449
9 21805200 22232100 8 1.0207
9 1.19E + 08 1.19E + 08 14 1.2975
10 47030100 47129100 9 0.7324
13 82995900 83045900 14 0.8358
15 18427100 20329200 11 1.3031
15 18427100 20089400 8 1.3899
20 23118700 28143700 3 1.4837
20 45623800 46285300 3 1.5193
22 26574200 27515100 1 1.6995
23 18654 2704240 2 1.1324
23 18654 2700830 10 1.1456
23 18654 2713630 6 1.1662
23 18654 2700830 19 1.19365
23 18654 2700830 22 1.2042
23 18654 2700830 12 1.2055
23 18654 2700830 20 1.2591
23 18654 2713390 14 1.27
23 18654 2700830 8 1.2776
23 18654 2700830 13 1.38107
Deletions marked in blue and amplifications in red.
Figure W1. Analysis of recurrent focal deletion at 9p showing involvement of CDKN2A, CDKN2B, and MTAP genes.
